Biosimilars

White House Unveils Plan to Lower Cost of Prescription Drugs

White House Unveils Plan to Lower Cost of Prescription Drugs

By

FDA Commissioner, Scott Gottlieb MD, said, "The FDA shares the goal of ensuring that American patients have access to quality and affordable care that meets their needs."

Guidelines for Biosimilar Use for Treatment of Rheumatologic Diseases

Guidelines for Biosimilar Use for Treatment of Rheumatologic Diseases

By

Consensus recommendations on the use of biosimilars for the treatment of patients with rheumatologic diseases were recently published in Annals of the Rheumatic Diseases.

Interchangeability Study Initiated for Adalimumab Biosimilar

Interchangeability Study Initiated for Adalimumab Biosimilar

By

Boehringer Ingelheim has initiated a clinical study to investigate the interchangeability between an adalimumab biosimilar candidate and Humira.

Concern Regarding Legislation Allowing Substitution of Biosimilars for Branded Drugs

Concern Regarding Legislation Allowing Substitution of Biosimilars for Branded Drugs

Much concern has been voiced regarding legislation allowing the substitution of biosimilars for branded drugs.

FDA Recommendations For Naming of Biologics

FDA Recommendations For Naming of Biologics

The FDA has issued a final guidance document for the naming of reference biological products and biosimilars.

Sign Up for Free e-Newsletters